Clinical trial · no report yet · Phase 3
Astefania
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- NCT04873362 ↗
- Active not recruiting
- Hoffmann-La Roche
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 6 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Atezolizumab; Trastuzumab Emtansine; Placebo; Trastuzumab
- Arms
- Arm A: Placebo + Trastuzumab Emtansine · Active comparator
- Arm B: Atezolizumab + Trastuzumab Emtansine · Experimental
- Enrollment
- 1,188
- Primary outcomes
- Invasive Disease-free Survival (IDFS) in the Full Analysis Set (FAS)
- Sponsor
- Hoffmann-La Roche
- Start
- May 4, 2021
- Primary completion
- Mar 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04873362 · updated Sep 3, 2026
Publications
linked from the registry- Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncol. 2022 Oct;18(32):3563-3572. doi: 10.2217/fon-2022-0485. Epub 2022 Nov 16. PubMed 36382554